Cancer Type: Thoracic
Study Type: Treatment
Phase: Phase II
Principal Investigator: Saltos, Andreas
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.
Primary Objective: Determine whether, in patients with TKI-naïve locally advanced or metastatic EGFR mutant NSCLC the addition of ramucirumab to osimertinib improves progression free survival, compared to osimertinib alone Secondary Objectives: Determine whether osimertinib plus ramucirumab improves objective response rate (ORR) compared with osimertinib alone. Determine whether osimertinib plus ramucirumab improves overall survival (OS) compared with osimertinib alone. Determine whether osimertinib plus ramucirumab improves disease control rate (DCR) compared with osimertinib alone. Determine the safety and tolerability of combining osimertinib with ramucirumab compared with osimertinib alone.
Immunotherapy; Therapy (NOS)
AZD9291 (Osimertinib); IMC-1121B (Ramucirumab); Osimertinib (); Ramucirumab ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
A secure website for patients to access their medical care at Moffitt.
An online resource for referring physicians and their staff.
For Moffitt faculty & staff members to access MoffittNet applications.
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday